Gevorg Tamamyan on the Visionary Leadership of Thomas L. Harrison and the Expanding Global Impact P53 Inc.
Gevorg Tamamyan, Editor-in-Chief and Co-Founder of OncoDaily, shared on LinkedIn:
”Thomas L. Harrison is one of the most accomplished figures in global healthcare communications.
As Chairman Emeritus of Diversified Agency Services (DAS), a division of Omnicom Group Inc., he led the world’s largest network of marketing services and communications companies overseeing more than 5,000 clients worldwide.
P53 Inc. is a U.S.-based innovator in medical media, scientific publishing, and research — proud home of OncoDaily™, OncoDaily TV, OncoDaily Medical Journal, CancerWorld Magazine, OncoDaily Magazine, OncoDaily IO, OncoDaily GI, Hemostasis Today, Fertility News, Boston Institute for Global Rankings (BIGR), Global Cancer Movement, Yvonne Award, OncoThon™, World Health Voices and VIRO.
With a mission to be the voice of medicine and a vision to become the fastest growing, most reliable, and innovative global source of medical information — where “everyone has a space to shape the future of medicine and healthcare” — P53 Inc. continues to expand its leadership across oncology, hemostasis, fertility, and biomedical innovation.
Within five years, P53 Inc. plans to evolve into a global multichannel healthcare media technology company operating 50 active brands across key medical verticals.”
Read the full announcement in OncoDaily.
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 14:16Hyperfibrinolysis as an Underrecognized Cause of Bleeding
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval